Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 410 participants.

Also called NCT05305612

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 410 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05305612
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT05305612. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-13 (actual); primary completion 2027-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions
Acronym
STOP CLOT
Condition
Mitral Regurgitation
Condition
Anticoagulation
Intervention (Other)
early anticoagulation
Intervention (Other)
late anticoagulation
Lead sponsor
National Institute of Cardiology, Warsaw, Poland (class: other)
Collaborator
Medical Research Agency, Poland (class: other government)
Collaborator
Soft Communication, Poland (class: not stated)

Record details

Record id
cardio:ct-nct05305612
Content hash
814c5107773f34f4f5b7015e09814b88ccc3bc8eccb5b787e2435fc70664791c